711 related articles for article (PubMed ID: 25476752)
1. Nucleo-cytoplasmic transport as a therapeutic target of cancer.
Gravina GL; Senapedis W; McCauley D; Baloglu E; Shacham S; Festuccia C
J Hematol Oncol; 2014 Dec; 7():85. PubMed ID: 25476752
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of CRM1-dependent nuclear export sensitizes malignant cells to cytotoxic and targeted agents.
Turner JG; Dawson J; Cubitt CL; Baz R; Sullivan DM
Semin Cancer Biol; 2014 Aug; 27():62-73. PubMed ID: 24631834
[TBL] [Abstract][Full Text] [Related]
3. Nuclear export of proteins and drug resistance in cancer.
Turner JG; Dawson J; Sullivan DM
Biochem Pharmacol; 2012 Apr; 83(8):1021-32. PubMed ID: 22209898
[TBL] [Abstract][Full Text] [Related]
4. XPO1/CRM1-selective inhibitors of nuclear export (SINE) reduce tumor spreading and improve overall survival in preclinical models of prostate cancer (PCa).
Gravina GL; Tortoreto M; Mancini A; Addis A; Di Cesare E; Lenzi A; Landesman Y; McCauley D; Kauffman M; Shacham S; Zaffaroni N; Festuccia C
J Hematol Oncol; 2014 Oct; 7():46. PubMed ID: 25284315
[TBL] [Abstract][Full Text] [Related]
5. KPT-330 inhibitor of XPO1-mediated nuclear export has anti-proliferative activity in hepatocellular carcinoma.
Zheng Y; Gery S; Sun H; Shacham S; Kauffman M; Koeffler HP
Cancer Chemother Pharmacol; 2014 Sep; 74(3):487-95. PubMed ID: 25030088
[TBL] [Abstract][Full Text] [Related]
6. Targeting Nuclear Exporter Protein XPO1/CRM1 in Gastric Cancer.
Sexton R; Mahdi Z; Chaudhury R; Beydoun R; Aboukameel A; Khan HY; Baloglu E; Senapedis W; Landesman Y; Tesfaye A; Kim S; Philip PA; Azmi AS
Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31569391
[TBL] [Abstract][Full Text] [Related]
7. Anti-tumor activity of selective inhibitors of XPO1/CRM1-mediated nuclear export in diffuse malignant peritoneal mesothelioma: the role of survivin.
De Cesare M; Cominetti D; Doldi V; Lopergolo A; Deraco M; Gandellini P; Friedlander S; Landesman Y; Kauffman MG; Shacham S; Pennati M; Zaffaroni N
Oncotarget; 2015 May; 6(15):13119-32. PubMed ID: 25948791
[TBL] [Abstract][Full Text] [Related]
8. A method for quantification of exportin-1 (XPO1) occupancy by Selective Inhibitor of Nuclear Export (SINE) compounds.
Crochiere ML; Baloglu E; Klebanov B; Donovan S; Del Alamo D; Lee M; Kauffman M; Shacham S; Landesman Y
Oncotarget; 2016 Jan; 7(2):1863-77. PubMed ID: 26654943
[TBL] [Abstract][Full Text] [Related]
9. Selective inhibitors of nuclear export (SINE)--a novel class of anti-cancer agents.
Parikh K; Cang S; Sekhri A; Liu D
J Hematol Oncol; 2014 Oct; 7():78. PubMed ID: 25316614
[TBL] [Abstract][Full Text] [Related]
10. Anti-tumor efficacy of Selinexor (KPT-330) in gastric cancer is dependent on nuclear accumulation of p53 tumor suppressor.
Subhash VV; Yeo MS; Wang L; Tan SH; Wong FY; Thuya WL; Tan WL; Peethala PC; Soe MY; Tan DSP; Padmanabhan N; Baloglu E; Shacham S; Tan P; Koeffler HP; Yong WP
Sci Rep; 2018 Aug; 8(1):12248. PubMed ID: 30115935
[TBL] [Abstract][Full Text] [Related]
11. Verdinexor (KPT-335), a Selective Inhibitor of Nuclear Export, Reduces Respiratory Syncytial Virus Replication
Jorquera PA; Mathew C; Pickens J; Williams C; Luczo JM; Tamir S; Ghildyal R; Tripp RA
J Virol; 2019 Feb; 93(4):. PubMed ID: 30541831
[TBL] [Abstract][Full Text] [Related]
12. SINE (selective inhibitor of nuclear export)--translational science in a new class of anti-cancer agents.
Gerecitano J
J Hematol Oncol; 2014 Oct; 7():67. PubMed ID: 25281264
[TBL] [Abstract][Full Text] [Related]
13. Understanding XPO1 target networks using systems biology and mathematical modeling.
Muqbil I; Kauffman M; Shacham S; Mohammad RM; Azmi AS
Curr Pharm Des; 2014; 20(1):56-65. PubMed ID: 23530499
[TBL] [Abstract][Full Text] [Related]
14. Biologic activity of the novel orally bioavailable selective inhibitor of nuclear export (SINE) KPT-335 against canine melanoma cell lines.
Breit MN; Kisseberth WC; Bear MD; Landesman Y; Kashyap T; McCauley D; Kauffman MG; Shacham S; London CA
BMC Vet Res; 2014 Jul; 10():160. PubMed ID: 25022346
[TBL] [Abstract][Full Text] [Related]
15. Preclinical antitumor efficacy of selective exportin 1 inhibitors in glioblastoma.
Green AL; Ramkissoon SH; McCauley D; Jones K; Perry JA; Hsu JH; Ramkissoon LA; Maire CL; Hubbell-Engler B; Knoff DS; Shacham S; Ligon KL; Kung AL
Neuro Oncol; 2015 May; 17(5):697-707. PubMed ID: 25366336
[TBL] [Abstract][Full Text] [Related]
16. Deciphering mechanisms of drug sensitivity and resistance to Selective Inhibitor of Nuclear Export (SINE) compounds.
Crochiere M; Kashyap T; Kalid O; Shechter S; Klebanov B; Senapedis W; Saint-Martin JR; Landesman Y
BMC Cancer; 2015 Nov; 15():910. PubMed ID: 26573568
[TBL] [Abstract][Full Text] [Related]
17. Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone.
Muqbil I; Aboukameel A; Elloul S; Carlson R; Senapedis W; Baloglu E; Kauffman M; Shacham S; Bhutani D; Zonder J; Azmi AS; Mohammad RM
Cancer Lett; 2016 Dec; 383(2):309-317. PubMed ID: 27693556
[TBL] [Abstract][Full Text] [Related]
18. Clinical Implications of Targeting XPO1-mediated Nuclear Export in Multiple Myeloma.
Gandhi UH; Senapedis W; Baloglu E; Unger TJ; Chari A; Vogl D; Cornell RF
Clin Lymphoma Myeloma Leuk; 2018 May; 18(5):335-345. PubMed ID: 29610030
[TBL] [Abstract][Full Text] [Related]
19. Nuclear retention of Fbw7 by specific inhibitors of nuclear export leads to Notch1 degradation in pancreatic cancer.
Gao J; Azmi AS; Aboukameel A; Kauffman M; Shacham S; Abou-Samra AB; Mohammad RM
Oncotarget; 2014 Jun; 5(11):3444-54. PubMed ID: 24899509
[TBL] [Abstract][Full Text] [Related]
20. The Second-Generation Exportin-1 Inhibitor KPT-8602 Demonstrates Potent Activity against Acute Lymphoblastic Leukemia.
Vercruysse T; De Bie J; Neggers JE; Jacquemyn M; Vanstreels E; Schmid-Burgk JL; Hornung V; Baloglu E; Landesman Y; Senapedis W; Shacham S; Dagklis A; Cools J; Daelemans D
Clin Cancer Res; 2017 May; 23(10):2528-2541. PubMed ID: 27780859
[No Abstract] [Full Text] [Related]
[Next] [New Search]
